# Activity of Sorafenib in Salivary Gland Cancer

> **NCT01703455** · PHASE2 · COMPLETED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 37 (actual)

## Conditions studied

- Salivary Gland Cancer

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01703455
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-10
- **Final completion:** 2013-01
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01703455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01703455, "Activity of Sorafenib in Salivary Gland Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01703455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*